Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

polyClustR: defining communities of reconciled cancer subtypes with biological and prognostic significance.

Eason K, Nyamundanda G, Sadanandam A.

BMC Bioinformatics. 2018 May 25;19(1):182. doi: 10.1186/s12859-018-2204-4.

2.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N.

Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.

PMID:
29472484
3.

A Novel Statistical Method to Diagnose, Quantify and Correct Batch Effects in Genomic Studies.

Nyamundanda G, Poudel P, Patil Y, Sadanandam A.

Sci Rep. 2017 Sep 7;7(1):10849. doi: 10.1038/s41598-017-11110-6.

4.

A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.

Battersby NJ, Dattani M, Rao S, Cunningham D, Tait D, Adams R, Moran BJ, Khakoo S, Tekkis P, Rasheed S, Mirnezami A, Quirke P, West NP, Nagtegaal I, Chong I, Sadanandam A, Valeri N, Thomas K, Frost M, Brown G.

Trials. 2017 Aug 29;18(1):394. doi: 10.1186/s13063-017-2085-2.

5.

Molecular subtypes in cancers of the gastrointestinal tract.

Bijlsma MF, Sadanandam A, Tan P, Vermeulen L.

Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):333-342. doi: 10.1038/nrgastro.2017.33. Epub 2017 Apr 12. Review.

PMID:
28400627
6.

Stable plastid transformation in Scoparia dulcis L.

Muralikrishna N, Srinivas K, Kumar KB, Sadanandam A.

Physiol Mol Biol Plants. 2016 Oct;22(4):575-581. doi: 10.1007/s12298-016-0386-7. Epub 2016 Oct 21.

7.

Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?

Eason K, Sadanandam A.

Cancer Res. 2016 Sep 15;76(18):5195-200. doi: 10.1158/0008-5472.CAN-16-0141. Review.

8.

Biolistic transformation of Scoparia dulcis L.

Srinivas K, Muralikrishna N, Kumar KB, Raghu E, Mahender A, Kiranmayee K, Yashodahara V, Sadanandam A.

Physiol Mol Biol Plants. 2016 Jan;22(1):61-8. doi: 10.1007/s12298-016-0338-2. Epub 2016 Jan 20.

9.

The consensus molecular subtypes of colorectal cancer.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S.

Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.

10.

A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.

Sadanandam A, Wullschleger S, Lyssiotis CA, Grötzinger C, Barbi S, Bersani S, Körner J, Wafy I, Mafficini A, Lawlor RT, Simbolo M, Asara JM, Bläker H, Cantley LC, Wiedenmann B, Scarpa A, Hanahan D.

Cancer Discov. 2015 Dec;5(12):1296-313. doi: 10.1158/2159-8290.CD-15-0068. Epub 2015 Oct 7.

11.

Reply to Colorectal cancer classification based on gene expression is not associated with FOLFIRI response.

Sadanandam A, Gray J, Hanahan D.

Nat Med. 2014 Nov;20(11):1231-2. doi: 10.1038/nm.3742. No abstract available.

PMID:
25375919
12.

Semaphorin 5A mediated cellular navigation: connecting nervous system and cancer.

Purohit A, Sadanandam A, Myneni P, Singh RK.

Biochim Biophys Acta. 2014 Dec;1846(2):485-93. doi: 10.1016/j.bbcan.2014.09.006. Epub 2014 Sep 28. Review.

13.

Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.

Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, Chang Q, Chu GC, Al-Khalil R, Jiang S, Xia H, Fletcher-Sananikone E, Lim C, Horwitz GI, Viale A, Pettazzoni P, Sanchez N, Wang H, Protopopov A, Zhang J, Heffernan T, Johnson RL, Chin L, Wang YA, Draetta G, DePinho RA.

Cell. 2014 Jul 3;158(1):185-197. doi: 10.1016/j.cell.2014.06.003. Epub 2014 Jun 19.

14.

Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications.

Sadanandam A, Wang X, de Sousa E Melo F, Gray JW, Vermeulen L, Hanahan D, Medema JP.

Cell Cycle. 2014;13(3):353-7. doi: 10.4161/cc.27769. Epub 2014 Jan 9.

15.

Identification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis.

Hunter KE, Quick ML, Sadanandam A, Hanahan D, Joyce JA.

PLoS One. 2013 May 14;8(5):e64472. doi: 10.1371/journal.pone.0064472. Print 2013.

16.

A colorectal cancer classification system that associates cellular phenotype and responses to therapy.

Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D.

Nat Med. 2013 May;19(5):619-25. doi: 10.1038/nm.3175. Epub 2013 Apr 14.

17.

Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?

Sadanandam A, Lal A, Benz SC, Eppenberger-Castori S, Scott G, Gray JW, Spellman P, Waldman F, Benz CC.

Breast Cancer Res Treat. 2012 Dec;136(3):693-703. doi: 10.1007/s10549-012-2290-3. Epub 2012 Oct 27.

18.

Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation.

Sadanandam A, Sidhu SS, Wullschleger S, Singh S, Varney ML, Yang CS, Ashour AE, Batra SK, Singh RK.

Br J Cancer. 2012 Jul 24;107(3):501-7. doi: 10.1038/bjc.2012.298. Epub 2012 Jul 10.

19.

In silico evaluation of TERT inhibition by anticancer drugs.

Mahendar P, Sirisha K, Kulandaivelu U, Shankar PL, Radhika T, Sadanandam A.

J Mol Model. 2012 Oct;18(10):4739-44. doi: 10.1007/s00894-012-1455-7. Epub 2012 Jun 6.

PMID:
22669532
20.

Subtype and pathway specific responses to anticancer compounds in breast cancer.

Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2724-9. doi: 10.1073/pnas.1018854108. Epub 2011 Oct 14.

21.

A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling.

Sadanandam A, Futakuchi M, Lyssiotis CA, Gibb WJ, Singh RK.

BMC Cancer. 2011 Jul 20;11:304. doi: 10.1186/1471-2407-11-304.

22.

Molecular docking studies and in vitro screening of new dihydropyridine derivatives as human MRP1 inhibitors.

Sirisha K, Shekhar MC, Umasankar K, Mahendar P, Sadanandam A, Achaiah G, Reddy VM.

Bioorg Med Chem. 2011 May 15;19(10):3249-54. doi: 10.1016/j.bmc.2011.03.051. Epub 2011 Mar 26.

PMID:
21530277
23.

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.

Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW.

Nat Med. 2011 Apr;17(4):500-3. doi: 10.1038/nm.2344. Epub 2011 Apr 3.

24.

Prediction of epigenetically regulated genes in breast cancer cell lines.

Loss LA, Sadanandam A, Durinck S, Nautiyal S, Flaucher D, Carlton VE, Moorhead M, Lu Y, Gray JW, Faham M, Spellman P, Parvin B.

BMC Bioinformatics. 2010 Jun 4;11:305. doi: 10.1186/1471-2105-11-305.

25.

The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer.

Hu Z, Huang G, Sadanandam A, Gu S, Lenburg ME, Pai M, Bayani N, Blakely EA, Gray JW, Mao JH.

Breast Cancer Res. 2010;12(2):R18. doi: 10.1186/bcr2487. Epub 2010 Mar 8.

26.

High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis.

Sadanandam A, Varney ML, Singh S, Ashour AE, Moniaux N, Deb S, Lele SM, Batra SK, Singh RK.

Int J Cancer. 2010 Sep 1;127(6):1373-83. doi: 10.1002/ijc.25166. Erratum in: Int J Cancer. 2012 Jun 15;130(12):E2.

27.

A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.

Kuo WL, Das D, Ziyad S, Bhattacharya S, Gibb WJ, Heiser LM, Sadanandam A, Fontenay GV, Hu Z, Wang NJ, Bayani N, Feiler HS, Neve RM, Wyrobek AJ, Spellman PT, Marton LJ, Gray JW.

BMC Med. 2009 Dec 14;7:77. doi: 10.1186/1741-7015-7-77.

28.

Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis.

Sadanandam A, Rosenbaugh EG, Singh S, Varney M, Singh RK.

Microvasc Res. 2010 Jan;79(1):1-9. doi: 10.1016/j.mvr.2009.10.005. Epub 2009 Oct 19.

29.

Enhanced expression and shedding of receptor activator of NF-kappaB ligand during tumor-bone interaction potentiates mammary tumor-induced osteolysis.

Nannuru KC, Futakuchi M, Sadanandam A, Wilson TJ, Varney ML, Myers KJ, Li X, Marcusson EG, Singh RK.

Clin Exp Metastasis. 2009;26(7):797-808. doi: 10.1007/s10585-009-9279-2. Epub 2009 Jul 10.

PMID:
19590968
30.

Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion.

Singh S, Sadanandam A, Varney ML, Nannuru KC, Singh RK.

Int J Cancer. 2010 Jan 15;126(2):328-36. doi: 10.1002/ijc.24714.

31.

CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion.

Singh S, Nannuru KC, Sadanandam A, Varney ML, Singh RK.

Br J Cancer. 2009 May 19;100(10):1638-46. doi: 10.1038/sj.bjc.6605055. Epub 2009 Apr 28.

32.

Identification of semaphorin 5A interacting protein by applying apriori knowledge and peptide complementarity related to protein evolution and structure.

Sadanandam A, Varney ML, Singh RK.

Genomics Proteomics Bioinformatics. 2008 Dec;6(3-4):163-74. doi: 10.1016/S1672-0229(09)60004-8.

33.

Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.

Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R, Singh RK.

Clin Cancer Res. 2009 Apr 1;15(7):2380-6. doi: 10.1158/1078-0432.CCR-08-2387. Epub 2009 Mar 17.

34.

Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation.

Futakuchi M, Nannuru KC, Varney ML, Sadanandam A, Nakao K, Asai K, Shirai T, Sato SY, Singh RK.

Cancer Sci. 2009 Jan;100(1):71-81. doi: 10.1111/j.1349-7006.2008.01012.x. Epub 2008 Nov 25.

35.

Impact of PsbTc on forward and back electron flow, assembly, and phosphorylation patterns of photosystem II in tobacco.

Umate P, Fellerer C, Schwenkert S, Zoryan M, Eichacker LA, Sadanandam A, Ohad I, Herrmann RG, Meurer J.

Plant Physiol. 2008 Nov;148(3):1342-53. doi: 10.1104/pp.108.126060. Epub 2008 Sep 19.

36.

Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.

Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK.

Cancer Res. 2008 Jul 15;68(14):5803-11. doi: 10.1158/0008-5472.CAN-07-5889.

37.

MCAM: a database to accelerate the identification of functional cell adhesion molecules.

Sadanandam A, Pal SN, Ziskovsky J, Hegde P, Singh RK.

Cancer Inform. 2008;6:47-50. Epub 2008 Mar 31.

38.

Chemokines in tumor angiogenesis and metastasis.

Singh S, Sadanandam A, Singh RK.

Cancer Metastasis Rev. 2007 Dec;26(3-4):453-67. Review.

39.

CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors.

Ashour AE, Lin X, Wang X, Turnquist HR, Burns NM, Tuli A, Sadanandam A, Suleiman K, Singh RK, Talmadge JE, Solheim JC.

Cancer Biol Ther. 2007 Aug;6(8):1206-10. Epub 2007 May 7.

PMID:
17617742
40.
41.

Induction of multiple shoots from leaf segments, in vitro-flowering and fruiting of a dwarf tomato (Lycopersicon esculentum).

Rao KV, Kiranmayee K, Pavan U, Sree TJ, Rao AV, Sadanandam A.

J Plant Physiol. 2005 Aug;162(8):959-62.

PMID:
16146322
42.

Nitrosomethylurea induced streptomycin resistance in Lycopersicon esculentum Mill.

Rao AV, JayaSree T, Ramesh M, Pavan U, Sadanandam A.

Indian J Exp Biol. 2000 Jun;38(6):617-20.

PMID:
11116537
43.

EMS-induced streptomycin resistance in Solanum melongena.

Rao AV, Farooqui A, Sree TJ, Ramana RV, Sadanandam A.

Theor Appl Genet. 1993 Dec;87(4):527-30. doi: 10.1007/BF00215099.

PMID:
24190326
44.

A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis.

Ottesen EA, Vijayasekaran V, Kumaraswami V, Perumal Pillai SV, Sadanandam A, Frederick S, Prabhakar R, Tripathy SP.

N Engl J Med. 1990 Apr 19;322(16):1113-7.

Supplemental Content

Loading ...
Support Center